Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiauranib Plus Albumin-paclitaxel and Gemcitabine in Advanced Pancreatic Cancer
NCT06492915Phase 2Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Aug 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of chiauranib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Akeso, Inc. Primary endpoint: Progression-Free Survival at 1 year. Started Aug 2024; status: active, not recruiting.
02
Drugs
chiauranib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06492915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492915.